Norway
· Delayed Price · Currency is NOK Gentian Diagnostics ASA Company Description
Gentian Diagnostics ASA develops, manufactures, and sells biochemical reagents for use in medical diagnostics and research in the United States, Asia, and Europe.
The company offers in-vitro diagnostic reagents for clinical chemistry analyzers, such as Gentian Circulating Calprotectin Immunoassay, a turbidimetric assay used for the measurement of calprotectin in plasma and serum for detection and assessment of inflammation; Gentian Cystatin C Immunoassay test kit, a GFR marker for the diagnosis and therapeutic control of renal function and chronic kidney disease; Gentian Retinol-Binding Protein Immunoassay for detection of retinol-binding protein in human serum and plasma; and Canine CRP Immunoassay test kit, a particle-enhanced turbidimetric immunoassay for quantitative determination of canine C-reactive protein in dog plasma and serum.
It also develops NT-proBNP Immunoassay, an aid in the diagnosis, monitoring, and assessment of severity in individuals suspected of having congestive heart failure, which is in product development phase.
In addition, the company provides faecal calprotectin immunoassay turbo that offers results of calprotectin concentration in stool supporting diagnosis of inflammatory bowel disease; and faecal pancreatic elastase immunoassay turbo, which allows analysis of pancreatic elastase in stool to aid in diagnosis of pancreatic exocrine insufficiency.
Gentian Diagnostics ASA was founded in 2001 and is headquartered in Moss, Norway.
| Country | Norway |
| Founded | 2001 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 63 |
| CEO | Matti Heinonen |
Contact Details
Address: BjOernAsveien 5 Moss, 1596 Norway | |
| Phone | 47 99 33 99 05 |
| Website | gentian.com |
Stock Details
| Ticker Symbol | GENT |
| Exchange | Oslo Børs |
| Fiscal Year | January - December |
| Reporting Currency | NOK |
| ISIN Number | NO0010748866 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Matti Heinonen | Chief Executive Officer |
| Njaal Kind | Chief Financial Officer and Chief Operating Officer |
| Frank Frantzen | Chief Technology Officer |
| Dr. Aleksandra Havelka | Chief Scientific Officer |
| Markus Jaquemar | Chief Growth Officer |
| Dr. Tom Nilsen | Head of Product Development |